Clinical trial
A Phase I Dose Escalation Study of VS-4718, A Focal Adhesion Kinase Inhibitor, In Subjects With Relapsed or Refractory Acute Myeloid Leukemia or B-Cell Acute Lymphoblastic Leukemia
NCT02215629 is registered in ClinicalTrials.gov with Verastem, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I Dose Escalation Study of VS-4718, A Focal Adhesion Kinase Inhibitor, In Subjects With Relapsed or Refractory Acute Myeloid Leukemia or B-Cell Acute Lymphoblastic Leukemia
- Lead sponsor
- Verastem, Inc.
- Phase
- Phase 1
- Overall status
- Withdrawn
- Start date
- Not reported
- Completion date
- November 30, 2016
- Enrollment
- 0 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
relapsed or refractory acute myeloid leukemia, relapsed or refractory b-cell acute lymphoblastic leukemia